Aurinia Pharmaceuticals Inc. (AUPH) Stock Ticker
AUPH right now
Market factors today
Unlock the full AUPH picture
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
AUPH stock facts
| Ticker symbol | AUPH |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.1B |
| CEO | Kevin C. Tang |
| Employees | 128 |
| Headquarters | Edmonton, AB, CA |
| IPO date | 2014-09-03 |
| Website | www.auriniapharma.com |
What you can see for AUPH on Tickr
Live AUPH price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AUPH report.
Rankings
FAQ
What is the ticker symbol for Aurinia Pharmaceuticals Inc.?
The ticker symbol for Aurinia Pharmaceuticals Inc. is AUPH, listed on the NASDAQ Global Market.
What is AUPH?
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an…